Category: 13625-39-3

Downstream synthetic route of 13625-39-3

13625-39-3 1,3,8-Triazaspiro[4.5]decane-2,4-dione 120989, apiperidines compound, is more and more widely used in various fields.

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13625-39-3,1,3,8-Triazaspiro[4.5]decane-2,4-dione,as a common compound, the synthetic route is as follows.

13625-39-3, To a suspension of l ,3,8~triazaspiro[4.5]decane-2,4-dione (CAS 13625-39-3, 20 mg, 1 18 mhio, eq. 1) and DIPEA (45.8 mg, 61.9 m, 355 pmol, eq. 3) in AVV-dimethylformamide (0.5 ml) was added 2-chlorobenzo[d]thiazole (22.1 mg, 130 mtho, eq 1.1) The reaction mixture was stirred at 120 C for 2 hours. The reaction mixture was poured into a mixture of ethylacetate/tetrahydrofuran (1 : 1) and the organic layer was washed with water and brine, dried over NazSCri and concentrated in vacuo. The crude material was purified by flash column chromatography (silica gel, eluent: 0 to 5% of methanol in dichloromethane) to afford 8- (benzo[d]thi azol-2-yl)- 1 ,3 , 8-tri azaspiro[4.5]decane-2,4-di one (11 mg, 36.4 mtho, 30.8 %) as a white solid. MS (ISP): 303.1 {I M 1 1 | }.

13625-39-3 1,3,8-Triazaspiro[4.5]decane-2,4-dione 120989, apiperidines compound, is more and more widely used in various fields.

Reference£º
Patent; C4 THERAPEUTICS, INC.; NASVESCHUK, Christopher, G.; DEY, Fabian; GOERGLER, Annick; KUHN, Bernd; NORCROSS, Roger; ROEVER, Stephan; SCHMID, Philipp; (270 pag.)WO2019/204354; (2019); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem

 

Analyzing the synthesis route of 13625-39-3

13625-39-3, As the paragraph descriping shows that 13625-39-3 is playing an increasingly important role.

13625-39-3, 1,3,8-Triazaspiro[4.5]decane-2,4-dione is a piperidines compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 2-1 10-(oxiran-2-ylmcthyl)-2-(trifluoromcthyl)- 10//-phcnothiazinc (100 mg, 0.31 mmol) and K2CO3 (214 mg, 1.55 mmol) in DMF (10 mL) was added 1,3,8- triazaspiro[4.5]decane-2,4-dione (210 mg, 1.24 mmol), and the reaction mixture was stirred at 80 C overnight. Then the mixture was concentrated to dryness. The residue was purified by prep- HPLC (Waters XBridge C18 (50 mm x 4.6 mm, 3.5 pm); A = H2O (0.01 mol/L NH4HCO3) and B = CH3CN; 15-95% B over 8 min) to afford a white solid (41 mg, 27% yield). MT-03 la NMR (400 MHz, . -DMSO) d ppm 8.69 (s, 1H), 7.36-7.34 (d, J= 7.6Hz, 1H), 7.28-7.17 (m, 4H), 7.05-6.98 (m, 2H), 5.26-5.25(d, J= 6.0 Hz, 1H), 4.12-4.10 (m, 1H), 3.97-3.92(m, 2H), 3.45-3.43(m, J= 6.4 Hz , 2H), 2.84-2.64 (m, 4H), 1.95 (s, 1H), 1.67-1.63 (m, 2H); 1.40-1.32 (m, 2H); LC-MS: Rt = 1.63 min; ESI m/z 493 [M+lf.

13625-39-3, As the paragraph descriping shows that 13625-39-3 is playing an increasingly important role.

Reference£º
Patent; CAMP4 THERAPEUTICS CORPORATION; BUMCROT, David, A.; SEHGAL, Alfica; HERTZOG, Donald L.; (172 pag.)WO2019/195789; (2019); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem